Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Aug;15(3):238–250. doi: 10.20892/j.issn.2095-3941.2017.0174

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

PMC Copyright notice

PVT1 inhibits the miR-214 expression by interacting with EZH2 in ovarian cancer cells. (A) PVT1 was enriched in the anti-EZH2 RIP fraction compared to the anti-IgG fraction in SKOV3 cells. (B) After PVT1 was knocked down, miR-214 was up-regulated in SKOV3 cells. (C) MiR-214 was significantly up-regulated after si-EZH2 was transfected into SKOV3 cells. (D) Chromatin immunoprecipitation (ChIP) method proved that PVT1 silencing decreased the binding ability between EZH2 and miR-214 promoter compared to IgG group. (E) The expression of miR-214 was decreased in PVT1 repressing SKOV3 cells using miR-214 inhibitor. (F) CCK-8 assay showed that si-PVT1 inhibited the proliferation of SKOV3 cells and miR-214 inhibitor could counteract the si-PVT1 inhibiting effect of SKOV3 cells. (G) Wound healing assay showed that si-PVT1 inhibited the migration of SKOV3 cells. However, miR-214 inhibitor could counteract the si-PVT1 inhibiting effect in SKOV3 cells. (H) Invasion assay showed that si-PVT1 inhibited the invasion of SKOV3 cells. However, miR-214 inhibitor could counteract the si-PVT1 inhibiting effect in SKOV3 cells (*P<0.05).